NEW YORK, May 27, 2026, 10:03 (EDT)
CooperCompanies (COO) traded 0.4% higher early on Nasdaq Wednesday at $62.28 after Goldman Sachs lowered its price target to $61 from $69, sticking with a Sell. That values the San Ramon, Calif. medical device company at $12.24 billion.
The timing is key. Cooper’s fiscal Q2 results hit in less than two weeks, due June 4 after the bell, with the earnings call scheduled for 5 p.m. ET. There’s not much new company news for investors right now, so the Goldman action puts a pre-earnings flag in the stock.
The trade lands in a U.S. week shortened by the holiday after equity markets were closed for Memorial Day on May 25. Nasdaq’s 2026 calendar does not show a closure for Wednesday, May 27.
CooperCompanies CooperCompanies posted first-quarter revenue of $1.024 billion, a 6% rise from last year. Non-GAAP EPS came in at $1.10. CEO Al White called it a “strong start to the fiscal year,” pointing to “robust cash flow.” The company set its fiscal 2026 adjusted EPS outlook at $4.58 to $4.66 and sees free cash flow at $600 million to $625 million.
The June report is now key. Cooper has been telling investors to move beyond weak spots in the portfolio and pay attention to margin improvement, stronger cash flow and premium contact lenses, with a focus on daily disposables.
The market is active. Earlier this year, Reuters said analysts saw Cooper, Alcon and Bausch + Lomb holding to steadier growth in 2026 as more buyers move from reusable contacts to higher-priced daily disposables. That shift is a key part of the bull case for CooperVision, Cooper’s contact-lens arm.
Shares traded sideways in the group. Alcon finished near flat at $67.69. Johnson & Johnson, known for Acuvue lenses, climbed 0.8% to $232.03. The Health Care Select Sector SPDR fund was up 0.7%, moving better than the SPDR S&P 500 ETF, which slipped a bit.
The downside risk hasn’t gone away. Sales in the second quarter need to pick up, and margins have to hold up against headwinds like tariffs, currencies, or slow demand overseas. If not, the stock could stick close to Goldman’s lower end. Cooper’s most recent 10-Q puts $1.5 billion still owed under the 2021 term loan and calls out a U.K. tax ruling after the quarter related to an old deal dispute—more signs that debt and legal issues are still around.
The stock isn’t cracking for now, but buyers aren’t giving it much credit either. The next main test comes June 4.
